SynthesisCurrent psychiatry reports2016
Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review.
Synthesis in Current psychiatry reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes.BMJ open · 2019Pooled it
- Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines.International journal of molecular sciences · 2016Pooled it
- Silexan is well-tolerated for long-term use in adults and for treatment of adolescents: a real-world data analysis.European archives of psychiatry and clinical neuroscience · 2026Article
- Patients Experience of Ear Acupuncture for Anxiety-A Qualitative Interview Study.Nursing research and practice · 2026Article
- Article
- Precision nanomedicine for anxiety: challenges, opportunities, and future directions in targeted drug delivery.Journal of food and drug analysis · 2025Review
- Difficult-to-Treat Anxiety: A Neurocomputational Framework.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025Review
- Gut-Brain Axis in Mood Disorders: A Narrative Review of Neurobiological Insights and Probiotic Interventions.Biomedicines · 2025Review
- Mixed drug overdose involving clonazepam, alprazolam, and olanzapine in a 72-year-old male with Parkinson's disease: a case report.Frontiers in neuroscience · 2025Article
- Anxiety-Like Behaviors in Mice Unmasked: Revealing Sex Differences in Anxiety Using a Novel Light-Heat Conflict Test.Journal of neuroscience research · 2024Article
- Randomized clinical trial: the effects of pregabalin for centrally mediated abdominal pain syndrome.Therapeutic advances in gastroenterology · 2023Article
- An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol.PloS one · 2022Article
- The lifetime prevalence and impact of generalized anxiety disorders in an epidemiologic Italian National Survey carried out by clinicians by means of semi-structured interviews.BMC psychiatry · 2021Article
- Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update.Therapeutic advances in psychopharmacology · 2021Review
- Use of clonazepam in REM sleep behavior disorder: association with fall-related injuries and alternative treatments.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020Article
- Panic Disorder as Unthinkable Emotions: Alexithymia in Panic Disorder, a Croatian Cross-Sectional Study.Frontiers in psychiatry · 2020Article
- Sleep therapeutics and neuropsychiatric illness.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Review
- Beyond Prescriptions Monitoring Programs: The Importance of Having the Conversation about Benzodiazepine Use.Journal of clinical medicine · 2019Article
- The Diagnosis and Treatment of Anxiety Disorders.Deutsches Arzteblatt international · 2018Article
- An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder.Annals of general psychiatry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many aspects of long-term pharmacological treatments for anxiety disorders (AnxDs) are still debated. We undertook an updated systematic review of long-term pharmacological studies on panic disorder (PD), generalized anxiety disorder (GAD), and social anxiety disorder (SAD). Relevant studies dating from January 1, 2012 to August 31, 2015 were identified using the PubMed database and a review of bibliographies. Of 372 records identified in the search, five studies on PD and 15 on GAD were included in the review. No studies on SAD were found. Our review confirms the usefulness of long-term pharmacological treatments for PD and GAD and suggests that they can provide further improvement over that obtained during short-term therapy. Paroxetine, escitalopram, and clonazepam can be effective for long-term treatment of PD. However, further studies are needed to draw conclusions about the long-term benzodiazepine use in PD, particularly for the possible cognitive side-effects over time. Pregabalin and quetiapine can be effective for long-term treatment of GAD, while preliminary suggestions emerged for agomelatine and vortioxetine. We did not find any evidence for determining the optimal length and/or dosage of medications to minimize the relapse risk. Few investigations have attempted to identify potential predictors of long-term treatment response. Personalized treatments for AnxDs can be implemented using predictive tools to explore those factors affecting treatment response/tolerability heterogeneity, including neurobiological functions/clinical profiles, comorbidity, biomarkers, and genetic features, and to tailor medications according to each patient's unique features.
Indexed as
Identifiers
26830881What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.